Payment overview · 2025
General Payments
$918.27
25 reported records · 8 companies
Healthcare provider profile · identity verified
Troy D Davis, D. O.
Allopathic & Osteopathic Physicians|Family Medicine · LITCHFIELD, MI · NPI 1871565085
Verified facts
What the public records show
CMS Open Payments records show Troy D Davis, D. O. received $918.27 in general payments during 2025 across 25 reported records.
Kerecis Limited accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $467.63 | 50.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.30 | 15.5% | 5 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $104.69 | 11.4% | 4 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $86.18 | 9.4% | 3 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $49.98 | 5.4% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $37.05 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.00 | 2.0% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $12.44 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $918.27 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $467.63 | 9 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $467.63 | 9 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $104.69 | 4 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $95.43 | 3 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $86.18 | 3 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $49.98 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $37.05 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $12.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 215 | 59 |
| Lisinopril | Lisinopril | 180 | 48 |
| Metformin Hcl | Metformin Hcl | 176 | 46 |
| Losartan Potassium | Losartan Potassium | 168 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 133 | 44 |
| Omeprazole | Omeprazole | 127 | 31 |
| Furosemide | Furosemide | 122 | 29 |
| Gabapentin | Gabapentin | 113 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 64 |
| Baclofen | Baclofen | 99 | 33 |
| Tramadol Hcl | Tramadol Hcl | 94 | 19 |
| Trazodone Hcl | Trazodone Hcl | 84 | 20 |
| Glipizide | Glipizide | 83 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 14 |
| Meloxicam | Meloxicam | 75 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Carvedilol | Carvedilol | 62 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 18 |
| Buspirone Hcl | Buspirone Hcl | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 56 | 17 |
| Glipizide Er | Glipizide | 52 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 16 |
| Lovastatin | Lovastatin | 49 | suppressed |
| Simvastatin | Simvastatin | 49 | 11 |
| Naproxen | Naproxen | 48 | 15 |
| Potassium Chloride | Potassium Chloride | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 46 | 32 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 15 |
| Allopurinol | Allopurinol | 41 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | 12 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 16 |
| Famotidine | Famotidine | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $918.27 · 25 records | Kerecis Limited | APLIGRAF, DALVANCE, EMBLAVEO, GRAFIX PL, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, MIRRAGEN ADVANCED WOUND MATRIX, Miro3D, TEFLARO, The Cologuard Plus Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error